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doi:10.1Objective: A bioresorbable polymeric film reduces the extent and severity of postoperative adhesions in infants
undergoing repeat sternotomy. Resorption of the bioresorbable polymeric film, however, leaves no barrier be-
tween the sternum and the epicardium. A sheet of expanded polytetrafluoroethylene is used by many surgeons
to create a physical barrier between the sternum and the cardiac structures. We hypothesized that placing
bioresorbable polymeric film beneath an expanded polytetrafluoroethylene pericardial membrane would both
decrease pericardial adhesions and provide a physical barrier.
Methods: A novel combination of bioresorbable polymeric film underneath an expanded polytetrafluoroethy-
lene membrane was tested in an established rabbit model of pericardial adhesion formation. After sternotomy,
a portion of pericardium was resected and the epicardium was abraded. Rabbits (n ¼ 36) were randomly as-
signed to 4 treatment groups: control group, no bioresorbable polymeric film or expanded polytetrafluoroethy-
lene; bioresorbable polymeric film group; expanded polytetrafluoroethylene group; and bioresorbable polymeric
filmþexpanded polytetrafluoroethylene group. At 4 weeks post-sternotomy, pericardial adhesions were scored
grossly for area and density of adhesions using an established 4-point (0–3) grading system.
Results:Thebioresorbable polymeric filmgrouphad a significant reduction inmeanadhesion score comparedwith
the control group (control¼ 2.86 0.37 vs bioresorbable polymeric film¼ 0.57 0.53, P<.0001) and expanded
polytetrafluoroethylene group (expanded polytetrafluoroethylene ¼ 2.75  0.46 vs bioresorbable polymeric
film ¼ 0.57  0.53, P<.0001). The bioresorbable polymeric filmþexpanded polytetrafluoroethylene group had
a low adhesion profile similar to the bioresorbable polymeric film group (bioresorbable polymeric filmþexpanded
polytetrafluoroethylene¼ 1.0 0, vs bioresorbable polymeric film¼ 0.57 0.53), but a considerably lowermean
adhesion score than the expanded polytetrafluoroethylene group (expanded polytetrafluoroethylene¼ 2.75 0.46,
vs bioresorbable polymeric filmþexpanded polytetrafluoroethylene ¼ 1.0  0, P<.0001).
Conclusions: Placement of bioresorbable polymeric film resulted in minimal pericardial adhesions compared
with controls. The placement of bioresorbable polymeric film underneath expanded polytetrafluoroethylene
at the time of sternal closure provides a novel combination to reduce the extent and severity of pericardial ad-
hesions while providing a physical barrier between the sternum and the cardiac structures. (J Thorac Cardiovasc
Surg 2011;141:789-95)T
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The Journal of Thoracic and Ca
Erepairs. Approximately 10% of current cardiac operations
involve repeat sternotomies.1 Unfortunately, the repeat me-
dian sternotomy is a risk factor for reentry injury to the pa-
tient because of the presence of adhesions that obscure
cardiac anatomy.2 Adverse events related to the reoperation
lead to poor patient outcome and higher cost.3 These com-
plications of reoperations have prompted experimental stud-
ies of how to prevent or decrease adhesion formation
and thus decrease the risks associated with reoperation.
Strategies for reducing reentry injury include insertion of
a permanent barrier-like expanded polytetrafluoroethylene
(ePTFE)4 and, more recently, the use of bioresorbable films
to reduce the extent and severity of adhesions.5,6 ePTFE can
provide a permanent barrier beneath the sternum to shield
the heart during future sternotomies.7 However, a strong in-
flammatory response underneath the ePTFE causes scarring
and fixation of the membrane to areas of the epicardium,rdiovascular Surgery c Volume 141, Number 3 789
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Swhich obscures the cardiac anatomy.2,7,8 The other
alternative is biodegradable polymeric film (BPF),
a composite of polyethylene glycol and polylactic acid,
which has been shown to reduce the incidence and
severity of retrosternal adhesions, but does not provide
a permanent barrier because it is resorbedwithin 28 days.9,10
This study examines a novel combination of BPF and
ePTFE to determine whether this combination has an ad-
vantage when compared with used alone by both decreasing
adhesion formation and creating a permanent prosthetic
barrier to protect from cardiac injury at sternal reentry.
We used a standard experimental rabbit model5,9,11 and
considered 4 treatment groups: (1) control, (2) BPF, (3)
ePTFE, and (4) BPFþ ePTFE. Each treatment group was
evaluated 4 weeks after surgery to assess the extent and
severity of adhesion formation by an independent
observer who was unaware of the treatment groups. In
addition, we performed blinded histology analysis that
quantified the neotissue fibrosis (NTF) formation on the
surface of the epicardium.12
MATERIALS AND METHODS
Membranes
BPF (REPEL-CVAdhesion Barrier; SyntheMed, Inc, Iselin, NJ), com-
posed of polyethylene glycol and polylactic acid in a ratio of 1.5:1, was
used in this study. The film was hydrated in sterile saline at room temper-
ature for 15 minutes and then cut into a 53 6-cm oval shape for use during
the surgery. ePTFE permanent prosthetic membrane (Gore PRECLUDE
Pericardial Membrane; WL Gore & Associates, Inc, Flagstaff, Ariz) was
similarly cut and inserted.
Animal Preparation
The Children’s Memorial Research Center Institutional Animal Care
and Use Committee approved this protocol. Thirty-six New Zealand white
female rabbits (4 kg) were randomly assigned to 1 of 4 groups: control
(n ¼ 9), BPF (n ¼ 9), ePTFE (n ¼ 9), and BPFþePTFE (n ¼ 9). Animals
were tranquilized with acepromazine (0.5 mg/kg subcutaneous) and gen-
eral anesthesia induced via ketamine (40 mg/kg) and xylazine (7 mg/kg),
followed by immediate endotracheal intubationwith a 3- or 4-mm tube. Af-
ter initial induction, anesthesia was maintained intraoperatively with 2%
isoflurane at 1 L/min via inhalation. Intravenous access to the marginal
ear vein was obtained, and animals were placed in a supine position for
continuous cardiorespiratory monitoring throughout the procedure.
Intraoperative Procedure
The fur was removed from the chest, and the chest was preppedwith Be-
tadine. A midline sternotomy incision was performed, and an anterior peri-
cardiotomy was performed from the left phrenic nerve to the right phrenic
nerve. The epicardial surface was abraded for 5 minutes with a gauze
square to produce punctuate bleeding and incite adhesion formation. In790 The Journal of Thoracic and Cardiovascular Surgthe control group, four 5-0 polypropylene sutures were placed at the
edge of the pericardium. In the BPF group, BPF was placed over the epi-
cardium and secured with four 5-0 sutures to the edge of the pericardium.
In the ePTFE group, ePTFE was similarly placed on the epicardium. In the
BPFþePTFE group, a combination of BPF underneath ePTFE was placed
on the epicardium and secured to the pericardial edge (Figure 1). After
treatment, a chest tube was temporarily inserted into the mediastinum
and then removed on suction once the sternum and the remaining tissues
were reapproximated.
Macroscopic Adhesion Evaluation
Four weeks after initial treatment, each rabbit was euthanized and un-
derwent repeat sternotomy. Retrosternal adhesion formation was assessed
visually at the apex, middle, and base of the central epicardial strip by an
independent observer who was blinded to the treatment method. Adhesion
density was qualitatively determined according to a standard adhesion
scoring scale: 0 ¼ no adhesions; 1 ¼ mild adhesions, easy to dissect;
2 ¼ moderate adhesions; 3 ¼ severe cohesive adhesions, difficult to
dissect.10
Microscopic Adhesion Evaluation
Samples of right ventricular epicardial tissue were obtained and fixed in
10% phosphate-buffered formalin, and then embedded in paraffin and
stained with hematoxylin–eosin for light microscopic evaluation to identify
the extent of neofibrosis on the epicardial surface. We quantified the adhe-
sion tissue thickness by determining the NTF thickness, composed of dense
collagen and adipose tissue.12 By using Masson trichrome staining, the
thickness of the NTF was analyzed by a blinded observer with the National
Institutes of Health Image program (version 1.62; National Institutes of
Health, Springfield, Va).
Statistical Methods
All data are presented as mean  standard deviation. Normally distrib-
uted data are compared by Student t test to analyze variance.RESULTS
The 36 rabbits had a sternotomy, were abraded for adhe-
sion formation, and then were treated according to the as-
signed group: control, BPF, ePTFE, or BPFþePTFE. One
rabbit in the BPF group had a technical issue with displace-
ment of the endotracheal tube during the operation, which
led to death. Thus, 35 rabbits (97.2%) survived the initial
surgery with no postoperative complications.Gross Examination
After 4 weeks, surviving rabbits (n ¼ 35) were eutha-
nized, a repeat sternotomy was performed, and gross exam-
ination was performed on the adhesions (Figure 2). In the
control group, highly tenacious adhesions formed through-
out the retrosternal region and dissection between the ster-
num and the epicardium was difficult, leading to injury to
the myocardium in some rabbits. In the BPF group, visually
there were fewer adhesions with a smooth epicardium that
facilitated an easy dissection. Some rabbits in this group ap-
peared to lack any adhesions, similar to the appearance at
the initial sternotomy. In the PTFE group, the adhesions
formed were nearly similar and dense as present in the con-
trol group. Finally, in the BPFþPTFE group, the adhesionsery c March 2011
FIGURE 1. Technique of securing the BPF and ePTFE layers to the pericardial edge (frontal view, left; cross-section, right). BPF,Biodegradable polymeric
film; ePTFE, expanded polytetrafluoroethylene.
Kaushal et al Evolving Technology/Basic Sciencewere minimal and a smooth epicardium was present that
was similar to the BPF group.
An independent observer who was unaware of the treat-
ment quantified the adhesions by using a 4-point scoring
system on 3 regions of the heart: apex, middle, and base
(Figure 3). The mean adhesion score in the control group
was 2.86  0.37. In contrast, the BPF group had a score
of 0.57  0.53, and the BPFþePTFE group had a similarly
low adhesion score of 1.0  0 with most of the adhesions
above the ePTFE, against the sternum. The ePTFE group
had a score of 2.75  0.46, similar to the control group.FIGURE 2. Operative photographs 4 weeks after initial surgery. The control g
region. The BPF group visually had fewer adhesions. In the ePTFE group, the ad
BPFþPTFE group, the adhesions were minimal and a smooth epicardium was
film; ePTFE, expanded polytetrafluoroethylene.
The Journal of Thoracic and CaIn addition, the ePTFE group had adhesions that were noted
between the epicardium and the ePTFE membrane, as well
as between the membrane and the sternum. None of the
groups had adhesions located at the posterior or lateral por-
tions of the heart. Furthermore, the regional distribution of
the adhesions within the heart was uniform between the
apex, middle, and base of the heart (Figure 4).
Therewas a significant reductionof adhesions between the
BPF and the control groups (control ¼ 2.86  0.37 vs
BPF¼ 0.57 0.53,P<.0001) and comparedwith the ePTFE
group (ePTFE ¼ 2.75  0.46 vs BPF ¼ 0.57  0.53,roup shows highly tenacious adhesions formed throughout the retrosternal
hesions formed were nearly similar and dense as in the control group. In the
present that was similar to the BPF group. BPF, Biodegradable polymeric





FIGURE 3. Bar graph showing mean adhesion score by treatment group.
The mean adhesion score in the control group was 2.86 0.37. In contrast,
the BPF group had a score of 0.57 0.53, and the BPFþePTFE group had
a similarly low adhesion score of 1.0 0. The ePTFE group had a score of
2.75 0.46, similar to the control group (control vs BPF, P<.0001; ePTFE
vs BPF, P<.0001; ePTFE vs BPFþePTFE, P<.0001; BPFþePTFE vs
BPF). BPF, Biodegradable polymeric film; ePTFE, expanded polytetra-
fluoroethylene.




SP<.0001).The BPFþePTFE group had a low adhesion pro-
file similar to the BPF group (BPFþ ePTFE ¼ 1.0  0 vs
BPF ¼ 0.57  0.53), but considerably fewer adhesionsFIGURE 4. Regions of heart assessed by observer blinded to treatment group (
the heart for each treatment group. BPF and BPFþePTFE groups had significantl
the heart) compared with the control and ePTFE only groups (control vs BPF,
BPFþePTFE vs BPF). BPF, Biodegradable polymeric film; ePTFE, expanded
panded polytetrafluoroethylene.
792 The Journal of Thoracic and Cardiovascular Surgthan the ePTFE group (BPF þ ePTFE ¼ 1.0  0 vs
ePTFE ¼ 2.75  0.46, P<.0001).
Microscopic Analysis
All specimens had an NTF layer composed of collagen
and adipose tissue that formed above the epicardium
(Figure 5). In the control group, a prominent, thick layer
of NTF had formed that was consistent with the macro-
scopic findings (Figures 4 and 5). In both the BPF and
BPF þ ePTFE groups, a thinner NTF layer was present
compared with the control group. In the ePTFE group,
a moderately thick layer of NTF was noted above the
epicardium, similar to the control group. There was
a significant difference in the mean adhesion tissue
thickness among the different groups (Figure 6). The
BPFþePTFE group showed significantly less tissue thick-
ness than both the control and ePTFE groups (BPFþePTFE
vs control, P<.001; BPFþ ePTFE vs ePTFE, P<.001),
whereas there was no significant difference between the
BPF and BPF þ ePTFE groups (P ¼ .08). The BPF-
treated group had less neo-tissue thickness than the ePTFE
group alone (P<.001), which was a statistically significant
difference.left). Bar graphs (right) showing mean adhesion tenacity at the 3 regions of
y lower adhesion tenacity at each of the 3 regions (base, middle, and apex of
P<.0001; ePTFE vs BPF, P<.0001; ePTFE vs BPFþePTFE, P<.0001;
polytetrafluoroethylene. BPF, Biodegradable polymeric film; ePTFE, ex-
ery c March 2011
FIGURE 5. With the use of hematoxylin–eosin staining, the thickness of the NTF was analyzed from samples of right ventricular epicardial tissue. NTF
layer was thinner in the BPF and BPFþePTFE treatment groups compared with the control and ePTFE only groups. BPF, Biodegradable polymeric film;
ePTFE, expanded polytetrafluoroethylene; NTF, neotissue fibrosis; AT, adipose tissue; Myo, myocardium.
Kaushal et al Evolving Technology/Basic ScienceDISCUSSION
This study demonstrated the efficacy of a bioresorbable
polymeric film to reduce adhesion density between the epi-
cardium and the sternum in a rabbit model. We further
showed that the combination of BPF and ePTFE was
equally effective in reducing adhesion density but also
provided a physical barrier for safer sternal reentry. ManyFIGURE 6. Bar graph showing mean adhesion thickness on the epicardial
surface of the heart for each treatment group and control group. The
BPFþ ePTFE group showed significantly less tissue thickness than both
the control and ePTFE groups (BPF þ ePTFE vs control, P < .0001;
BPFþePTFE vs ePTFE, P<.0001), whereas there was no significant dif-
ference between the BPF and BPFþePTFE groups (P¼ .08). A difference
was seen between the BPF group and the PTFE group (P<.0001). NTF,
Neotissue fibrosis.




Scongenital heart surgeons consider a physical barrier to be
important in preventing injury to underlying cardiac struc-
tures, such as conduits and malposed vessels. With BPF
placed underneath ePTFE, details of the epicardial cardiac
anatomy were preserved and not obscured, which is typi-
cally seen when ePTFE alone is placed under the sternum.
The combination of BPF and ePTFE elicits this effect by de-
creasing adhesion formation under the ePTFE, resulting in
a superior benefit than when either is used separately.
ePTFE provides a physical barrier, and BPF reduces the ex-
tent and severity of adhesions. These results have important
clinical implications for patients who are to undergo repeat
sternotomies.
Previous studies have determined that the optimal poly-
mer ratio for BPF is 1.5:1 polyethylene glycol to polylactic
acid.5,9 This maximizes the initial mechanical strength and
flexibility but allows for complete resorption by 28 days
post-implant. A recent prospective randomized trial of
BPF in patients with congenital cardiac disease demon-
strated safety and efficacy in reducing the extent and sever-
ity of postoperative adhesion formation.10 This material is
now approved by the Food and Drug Administration for pa-
tients aged 21 years or less who expect to undergo a repeat
sternotomy. Despite this success with BPF, a limitation is
that the film is resorbed, leaving no physical barrier between
the sternum and the epicardium. The combination of BPF
and ePTFE circumvents this limitation by decreasing adhe-
sion formation and providing a barrier for sternal reentry.rdiovascular Surgery c Volume 141, Number 3 793




SPatients with congenital cardiac disease are now living
longer after their initial or palliative operations, which
correlates with more repeat sternotomies for reoperations
or transplantation.2 The difficulty of repeat sternotomies
lies with adhesion formation between the sternum and
the epicardium that obscures the anatomy and thus predis-
poses to vascular injury, myocardial lacerations, and
increased morbidity.3 The genesis of mediastinal adhe-
sions is a multistep process that unfolds over a period
of 2 to 3 weeks. The presence of blood and serosal injury
initiates the formation of adhesions in the mediastinum.
Initially, an exudative phase exists with fluid, inflamma-
tory cells, and fibrin deposition. This is followed by a des-
quamation phase, with injury to the mesothelial cells and
aggregation of inflammatory cells adhering to mesothelial
cells along with further fibrin deposition. The third phase
is collagen deposition and blood vessel growth in the
newly formed connective tissue. The last phase is adhe-
sion formation. BPF decreases adhesions by providing
a temporary barrier to fibrin bridges connecting apposing
surfaces during the critical first several weeks after the
sternotomy.10
Several strategies have been proposed to reduce adhe-
sion formation: xenograft membranes, prosthetic mem-
branes, fibrolytic solutions, and resorbable membranes.13
Xenogenic materials have shown evidence of infection
and late calcification resulting in limited clinical use.14
Synthetic nonresorbable materials include ePTFE, silicone
rubber, polyethylene film, and Dacron mesh.4–7,15–17 The
most common synthetic material used in the clinical
setting is ePTFE, but this has a major limitation because
of a vigorous inflammatory reaction that creates
a fibrous capsule over the surface of the heart.7,17 Other
methods used to inhibit pericardial adhesions have
included fibrolytic agents that alter the balance between
fibrin deposition toward fibrin dissolution.11 A limitation
clinically for these fibrolytic solutions are the side effects
of bleeding and altered healing ability. Bioresorbable ma-
terials have an advantage based on their ability to prevent
adhesion formation with no foreign body response like
that seen with ePTFE. Hyaluronic acid biocompatible
membrane (Seprafilm, Genzyme, Cambridge, MA) was
shown to facilitate reoperations in complex congenital car-
diac surgery, but this study was not blinded or random-
ized.18 Naito and colleagues,12 from Tokyo Women’s
University, performed a similar study to ours but with Se-
prafilm (a hyaluronic acid bioabsorbable membrane). They
concluded that the combined use of Seprafilm with either
PTFE or autologous pericardium effectively reduced the
formation of pericardial adhesions beneath the physical
barrier. Their conclusions are similar to ours with a differ-
ent bioresorbable polymeric film that does not have Food
and Drug Administration approval for mediastinal
applications.794 The Journal of Thoracic and Cardiovascular SurgLimitations
Our study has several limitations. There are intrinsic dif-
ferences between the rabbit model and humans that will not
be solved until a human clinical trial is conducted. Another
limitation is that other contributing factors for adhesion for-
mation were lacking in this rabbit model (ie, cardiopulmo-
nary bypass). Finally, the duration of the study was 28 days,
which is far less than the shortest reoperation period of 3 to
6 months commonly observed in patients with congenital
cardiac disease undergoing single ventricle palliation
operations.CONCLUSIONS
Bioresorbable polymeric film in combination with
ePTFE reduced the extent and severity of adhesion forma-
tion between the heart and the ePTFE and provided a phys-
ical barrier during sternal reentry. With this novel
combination, ePTFE did not induce a capsule formation
over the heart, which typically obscures the anatomy of
the heart. These data suggest that the combination therapy
of BPF and ePTFE provides a unique method for preventing
adverse outcomes in cardiac reoperations and making ster-
nal reentry safer. A human clinical trial is needed to validate
this experimental model.
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DrGordon Cohen (Seattle, Wash). Because both the PTFE and
the BPF are commercially available, many surgeons have experi-
enced using one or the other or maybe even both, and not surpris-
ingly have an opinion as to why one is better than another.
However, I have yet to hear of this novel approach of anyone using
them both together. As is common in our specialty, we often just
start doing things because we think they are better, but you de-
signed a straightforward and practical study to try and actually an-
swer this question.
I have a few questions for you.
1. Out of curiosity, how do you blind the evaluator to the pres-
ence or absence or PTFE?
2. Is 4 weeks a long enough period for significant adhesions to
form? Is there some relationship between the different ma-
terials and time, that is, would it not have been better to eval-
uate the adhesions at different time points (eg, 1, 3, and 6
months) to really understand the differences?
3. You must have tried this combination in patients. What has
been your experience in actual clinical practice?
4. Finally, just an opinion, do you think that some sort of PTFE
and BPF combination should be a standard of care for pa-
tients who will certainly undergo repeat cardiac surgery?
Because it decreases the risk associated with reoperation
and potentially decreases time, which we could speculate
translates to a reduction in costs.
Dr Kaushal. The first question relates to the blinded observer.
I might have mentioned that in the text, but I have changed that
subsequently because of course you cannot have a blinded ob-
server to PTFE. The observer was actually independent and not
aware of each treatment group, so that is why we used that as an
observer. It was not blinded.
The second question asks why did I look at 4 weeks and was
there a long-lasting effect of preventing adhesions beyond the 1
month, to 3 or 6 months. The reason why I chose 4 weeks is thatThe Journal of Thoracic and Cawe have additional data that we did not present where we have
looked at the adhesion formation along an interval course, span-
ning 1, 3, and 6 months, and what we noticed was that there was
no difference of adhesion formation in that time period, so that
is why we subsequently reduced our evaluation to just 1 month.
Your third question involves the clinical utility of this and have
we used that in our patients. We have not used that currently. Our
plans are to start a clinical trial this fall. We think that using this
combination will prevent adhesion formation. I think the best
way to analyze something before it is the standard of care, which
deals with your fourth question, is that we have to rigorously study
this and make sure that it is safe and effective.
Speaker. If the physical barrier and BPF work sowell, have you
ever tried using a sandwich with BPF on one side and the other side
underneath the sternum so it prevents the adhesions and the PTFE
is in the middle?
Dr Kaushal. That is a very good thought, and in fact our next
set of experiments are exactly that. As I mentioned in our PTFE
group where we used the combination, there was adhesion forma-
tion between the sternum and the PTFE, so our thoughts were, as
you just mentioned, that maybewe can use a triple sandwich where
we use BPF, PTFE, and BPF to prevent adhesion formation
throughout that area.
Dr Pirooz Eghtesady (Cincinnati, Ohio). Two questions. What
is the cost for these 2 things, and, at least from my perspective, the
PTFE does a nice job ensuring safety during reentry, but a big pain
is when you have to dissect the right atrium off the pericardium,
dissect between the aorta and the pulmonary more down below.
Does this stuff sort of trickle down from the surface and prevent
those adhesions?
I do not know if one could do this. I think a corollary would be if
you want to make it clinical conversion either looking at the time it
takes to have a certain exposure if you did an animal study or injury
during that process as you were trying to set things up.
Dr Kaushal. I do not have the exact price for the BPF, but I can
get that for you if you require it.
Your second question deals with the healing properties of this
and whether you can apply it to different areas, especially the right
atrium. The healing quality of this is actually very good. The com-
pliance of this film is good in the sense that once you soak it for 5
minutes in saline it is pliable, and you can actually cut it to the
shape or size that you require and apply it to the areas you need,
so if you wanted to have more on the right atrium you can actually
do that. I think that is easy. We did not do that in this study.
The timing was actually looked at in the original study per-
formed with the infant surgeries in those patients, and there was
a decrease in time to perform the dissection of adhesion formation.
So that has been looked at in the clinical trial, but it is a good point.
We will look at that in the next trial we perform. I think as we have
gained experience with re-do sternotomies, our mortality rate has
definitely decreased, and there have been 2 different reports stating
the ease of a re-do, is that a risk factor for mortality, and it is not
really a risk factor anymore for mortality, but I think what will
come out of that is why we are pursuing this. This will be another
adjunct in preventing injuries that do not result in mortality but in
morbidity.rdiovascular Surgery c Volume 141, Number 3 795
